June 7, 2023

Grifols Egypt delivers first plasma medicines made from Egyptian plasma donations

  • Hospitals in Egypt to receive initial shipment of albumin, the start of what will be a steady stream of lifesaving therapeutics that will also include immunoglobulins and blood-clotting factors, all made from rising Egyptian plasma donations
  • New donation centers are opening – a total of 20 will be operational by the end of 2024 – and manufacturing facilities being built as part of world’s first integrated plasma-supply platform, a joint venture between Grifols and Egypt’s National Service Projects Organization
  • Grifols global leadership in creating innovative alliances between the plasma industry and the public sector is helpìng ensure domestic plasma strategic self-sufficiency

Barcelona, Spain, June 7, 2023 - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world’s leading producers of plasma-derived medicines with a more than 110-year track record of contributing to the health and well-being of people around the world, and Egypt’s National Service Projects Organization (NSPO) have announced that their first plasma-derived medicines, manufactured from Egyptian donations, are available to administer to Egyptian patients.

Hospitals in Egypt will soon receive large quantities of albumin, used in major surgery and to treat trauma and severe burns. The inaugural shipment begins what will be a constant supply of essential plasma therapies that will also include immunoglobulins (Ig) for immunodeficiencies and blood-clotting factors to manage bleeding disorders.

All will be made from the increasing amounts of plasma from Egyptians, whose donations for the time being are being manufactured into medicines in Grifols’ Parets del Vallès (Barcelona) plant as part of the landmark agreement that the company signed with the NSPO in November 2020.

The resulting joint venture, Grifols Egypt for Plasma Derivatives, is currently developing the world’s very first integrated plasma infrastructure, including donation centers and manufacturing facilities. Of the 20 donation centers planned, six are already up and running, with another four expected to be open by the end of this year and 10 more in 2024. Construction is also underway on plasma fractionation and purification plants, plus testing and warehouse operations, in the New Administrative Capital’s medical city.

Under the terms of the game-changing alliance, the Parets del Vallès plant is producing plasma medicines for export back to Egypt until construction of the new Egyptian manufacturing site is completed, expected to be at the end of 2025, and becomes operational.

“The manufacturing and delivery of plasma medicines for Egyptian patients with Egyptian plasma is a reality and a milestone in establishing an end-to-end plasma supply hub for Africa and the Middle East, said Raimon Grifols, Grifols Chief Corporate Officer.

“Today, and thanks to the generous donations of Egyptians, Egypt has taken a huge step forward in its vision to be a regional leader in plasma medicines and healthcare,” said Dr. Magdy Amin, CEO Grifols Egypt.

Through its Global Plasma Self-sufficiency Program Grifols continues to drive innovative alliances between the plasma industry and the public sector to ensure domestic plasma self-autonomy. Two years after forging its alliance with the Egyptian government, Grifols signed a pioneering long-term agreement with Canadian Blood Services, Canada’s national blood authority, to greatly increase the country’s self-sufficiency in Ig medicines through an all-Canadian supply and manufacturing infrastructure.